Academic Editor: Peter Kokkinos
The use of coronary physiology in patients with chronic coronary syndromes is highly variable, and the evidence base complex. Tests of coronary physiology have traditionally been invasive (e.g., fractional flow reserve), but novel non-invasive methods are now available which provide additional anatomical information (e.g., computed tomography-based fractional flow reserve and angiogram-derived physiology). This review summarises the evidence for and against the relative value of these tests for patients being investigated for chest pain that may represent chronic coronary syndromes, and for those triaged to percutaneous coronary intervention.
Coronary artery disease (CAD) is associated with the accumulation of atherosclerotic plaque in epicardial arteries and it presents as an acute or chronic coronary syndrome (CCS) [1]. CAD was the most common cause of death globally in 2019 and it affects over 2 million people in the United Kingdom alone [2, 3]. The accurate and efficient investigation and management of patients with CCS is therefore of considerable importance.
Investigation strategies for CCS rely on evaluation of (i) an imaging test (burden of atheroma), (ii) coronary physiology (burden of ischaemia), or (iii) both. Anatomical evaluation for the detection of atheroma has traditionally been performed using invasive coronary angiography (ICA), but advances in the diagnostic accuracy of computed tomography coronary angiography (CTCA) means that this test is able to identify atheromatous lesions with a similar level of accuracy in most cases [4]. However its application is limited in some patient groups, for example those with tachyarrhythmias or high body mass index. Invasive or non-invasive assessment of plaque vulnerability can additionally be used to provide further prognostic information [5, 6, 7, 8].
Physiological evaluation for the detection of ischaemia, or surrogates for
ischaemia, can be achieved using a variety of tests. Non-invasive investigations
include stress cardiac magnetic resonance, stress echocardiography, nuclear
myocardial perfusion scans and now, only rarely, exercise tolerance tests [1].
Invasive tests for surrogates of ischaemia have traditionally relied on the
intracoronary pressure wire, either using fractional flow reserve (FFR) or
non-hyperaemic indices such as instantaneous wave-free ratio (iFR) [9]. More
recently, complex computer models of fluid dynamics and 3D reconstruction have
facilitated tools that provide surrogates for ischaemia either non-invasively,
from the dataset created by a CTCA in the form of FFR
Given the diverse nature of the currently available tests with which to investigate patients presenting with new onset chest pain, and the rapidly increasing body of evidence, which has changed substantially recently, this review will address the relative pros and cons of the various approaches: invasive or non-invasive; anatomical or physiological?
Current clinical guidelines are discrepant in their recommendations, particularly in relation to their preference for anatomical or physiological testing of patients with CCS. The National Institute for Health and Care Excellence (NICE) CG95 guidelines (Chest Pain of Recent Onset) favour the use of CTCA for the investigation of the vast majority of patients with stable chest pain, except those with confirmed CAD [10]. By contrast, the European Society of Cardiology guidelines (2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes) encourage estimation of the pre-test probability of CAD based on the patient’s clinical presentation and risk factors [1]. Specifically, they recommend that those with a low clinical likelihood of obstructive CAD should be investigated with a CTCA, and those at greater risk should receive testing for ischaemia with either a functional non-invasive test or ICA with FFR/iFR. Invasive physiological assessment is particularly favoured for patients undergoing ICA with coronary stenoses of 50–90% or multivessel disease, where a mismatch between the angiographic and functional severity of a lesion is common [1].
Management plans for patients with CCS are derived from the results of these investigations. This decision-making process is complex, and must consider the merits of optimal medical therapy (OMT) versus revascularisation, percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) and which vessels require intervention. There is considerable, and recently discrepant, evidence about whether these decisions and the subsequent clinical outcomes are improved by using surrogates of ischaemia on top of angiographic appearance to inform them.
The initial dilemma facing clinicians tasked with assessing and managing patients with stable chest pain is whether to use a test of atheroma burden, ischaemia burden, or both. The ideal decision pathway is dominated by the need to provide optimal patient care but also is required, in most local health economies, to be demonstrably cost effective.
There is a plausible and logical case to be made that starting with a test of coronary anatomy that incorporates an overall assessment of atheroma burden and locality is dominant. To begin, such an approach establishes two fundamentally important facts: (a) is there an aberrant course for a coronary artery (usually between the aorta and pulmonary artery) that could explain chest pain and identify risk? And (b) are the coronaries clear of any atheroma? In patients who have no atheroma, classical angina can be excluded, and the implications regarding the lack of requirement for optimal medical therapy (OMT) and revascularisation are profound. The caveat to this is the expanding awareness of the prevalence of microvascular angina, which will not be addressed further in this review given limitations of space.
In patients who do prove to have a significant burden of atheroma, this provides a clear cut indication for the application of OMT. In this context, OMT comprises two components. Firstly, disease-modifying therapy including aspirin and a statin, the evidence for which are reviewed in reference [11]. Furthermore, given the results of the HOPE and EUROPA trials, there is an indication for ACE Inhibitors in most patients with coronary atheroma, regardless of left ventricular function [12, 13]. Secondly, anti-anginal drugs that are normally headed by beta blockers. The importance of OMT in the management and outcome of patients with CCS is well established by a variety of evidence sources. Apart from the data summarized in reference [11], the ability of this approach to yield clinical advantage is well established in the SCOT HEART trial [14]. In SCOT HEART, 4146 patients with stable chest pain were randomised to either standard care alone or CTCA as their first line test. After 5 years, the combined rate of death from CAD or non-fatal myocardial infarction (MI) was significantly lower in the CTCA group (hazard ratio 0.59; 95% CI 0.41–0.84) [15]. This was achieved despite similar overall rates of revascularisation, suggesting that the improved outcomes were due to better detection of CAD and the subsequent application of disease-modifying medical therapy [16]. It should be noted that the superior clinical outcome observed in the 5 year follow up was driven by non-fatal MI, rather than mortality. This may prove to be important, given the recent conflicting data about whether spontaneous myocardial infarction during follow up of patients with CAD is associated at some point with mortality.
On top of this evidence that favours a primarily anatomical approach linked with OMT, the results of the ISCHEMIA trial can be interpreted as supporting the concept that we could perhaps miss out ischaemia testing for most patients with stable angina in favour of this simpler algorithm [17]. This concept admittedly requires lateral thought and extrapolation, and we must also consider the limitations of the study including slow recruitment and lower than expected event rates. In ISCHEMIA, patients with stable angina were actually only meant to be included in the trial if they had at least moderate ischaemia burden at baseline. In fact, just over 10% had mild ischaemia or none at all. However, the trial reported that early angiography and revascularisation had no overall outcome advantage (using the complex primary composite endpoint of cardiovascular death, MI, hospitalisation for unstable angina or heart failure, and resuscitated out of hospital arrest) above and beyond application of OMT alone. Perhaps this population of patients with stable chest pain could have merely been triaged by CTCA alone as having important CAD and then been put on OMT without needing any other tests?
The power of OMT in its own right in the SCOT HEART and ISCHEMIA populations, and the outcome comparison to revascularisation in ISCHEMIA, makes a straightforward case for leading with detection of atheroma and application of OMT in all such patients as the default initial strategy. Later on in this review, we discuss a comparison of the prognostic value of atheroma burden versus ischaemia burden, but first we must review the evidence that ischaemia burden is of clinical value.
There is a persuasive body of evidence that collectively indicates that the burden of ischaemia is indeed associated with prognosis, although nearly all these data present composites of death plus MI, and analysis shows that significant outcomes are almost always driven by the MI component, rather than by mortality. For example, in patients with stable chest pain and coronary artery lesions who received myocardial perfusion imaging using stress single photon emission computed tomography (SPECT) sestamibi, annual rates of death or nonfatal MI were 12 times higher in those with ischaemia than in those with normal images (7.4% vs. 0.6%) [18]. The relationship between ischaemia burden and prognosis was also demonstrated in the COURAGE nuclear substudy, which recruited patients with significant stable CAD and evidence of ischaemia [19]. They underwent myocardial perfusion SPECT imaging before and at 6 to 18 months after treatment with either OMT and PCI, or OMT alone. An almost linear relationship was present between the risk of death or MI and the extent and severity of residual ischemia at the second scan. This ranged from 0% for patients with no ischemia, to 39.3% for patients with 10% or greater residual ischaemia of the myocardial mass at follow up.
Observational data also show that the extent of myocardial ischaemia is
associated with different survival rates for patients treated with OMT or
revascularisation. For example, a study of over 10,000 consecutive patients
undergoing exercise or adenosine stress myocardial perfusion SPECT imaging showed
a positive association between the amount of inducible ischaemia and cardiac
death rates for patients treated with OMT. This relationship was attenuated by
revascularisation. Consequently, OMT was preferrable for patients with no
inducible ischaemia (cardiac death rate 0.7% vs. 6.3%, statistically
non-significant p value) and revascularisation was preferable for
patients with greater than 20% myocardial ischaemia (cardiac death rate 2% vs.
6.7%, p
The pressure wire provides an extremely well validated surrogate for downstream myocardial ischaemia based upon the measured pressure drop across lesion(s) in a vessel, either in the form of FFR or iFR. The basic point of added value to obtaining information regarding vessel-specific, and, more recently, lesion-specific ischaemia, is that, outside the context of acute ST elevation MI, implantation of coronary stents has value only in lesions responsible for downstream ischaemia. This has been shown in a series of high quality randomised trials including DEFER, FAME and FAME2 [21, 22, 23].
The DEFER trial (Fractional Flow Reserve to Determine the Appropriateness of
Angioplasty in Moderate Coronary Stenosis) was the first randomised controlled
trial exploring the use of FFR to direct PCI [21]. It recruited 325 patients
referred for elective PCI with angiographically “significant” stenosis (
The FAME (Fractional Flow Reserve versus Angiography for Guiding Percutaneous
Coronary Intervention) and FAME2 (Fractional Flow Reserve–Guided PCI versus
Medical Therapy in Stable Coronary Disease) randomised trials also provide clear
evidence of clinical benefit for the use of coronary physiology using FFR in
populations who have been triaged to PCI based upon their angiographic
appearances [22, 23]. FAME recruited over 1000 patients with multivessel CAD due
to undergo PCI of lesions based on angiographic appearance. Patients were
randomised to angiographically-guided PCI of all indicated lesions, or FFR-guided
PCI of only those lesions with FFR
The FAME2 study explored whether patients with functionally significant stenosis
(FFR
For patients undergoing CABG, FFR-guidance does not appear to be quite so valuable. FFR-guided CABG results in fewer anastomoses per patient than for angiographically-guided procedures, but it does not carry any benefit in terms of major adverse cardiovascular event risk [26]. The recently published FAME3 study (Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery) recruited patients with angiographically identified three vessel disease. In this population, FFR-guided PCI was not shown to be non-inferior to CABG in terms of a composite of death, MI, stroke or repeat revascularisation at 1 year [27].
These trials have established some important principles in terms of the value of pressure wire measurement in patients who have already been triaged, on the basis of a diagnostic angiogram, to PCI. Firstly, stenting lesions that are non-ischaemic is associated with a worse outcome than treating them medically (DEFER), and that deferral of lesions that are non-ischaemic according to FFR or iFR is associated with a very good medium term outcome with low ischaemic event rates [21, 24, 25]. Secondly, that there is a lower event rate, driven by urgent revascularisation, in patients with pressure wire positive lesions if they are stented compared with if they are treated with OMT alone (FAME2) [23]. Finally, that pressure wire-directed multivessel PCI is associated with a significantly better clinical outcome (composite of death, MI and repeat revascularisation) than angiography-directed PCI, despite fewer stents being used in fewer vessels at lower overall cost in the former group (FAME) [22]. So, the ability of FFR (and iFR) to optimise PCI planning is extremely well established.
By what mechanism does the pressure wire affect our assessment and management of our patients? The correlation between the angiographic appearance of a lesion (i.e., its “significance”) and whether or not it is capable of causing downstream ischaemia is not close, so that there is a discrepancy in about 30% of lesions (Fig. 1, Ref. [28]). This observation has been made in a variety of patient populations, and the degree of discordance is remarkably consistent. Not surprisingly, this discordance has profound implications for the subsequent management of the vessels, and therefore patients. For example, in RIPCORD, which included 200 patients undergoing a diagnostic angiogram for stable chest pain, there was a change in management (between OMT alone, PCI, CABG or more information required) in 26% of patients when FFR of all the major epicardial coronary arteries was available when compared to the plan based upon the angiographic appearances alone [28]. This observation is consistent with a variety of other non-randomised studies, which demonstrate that the availability of some pressure wire data changes the management of the population in between a quarter and a half of the patients because of this effect [29].
Concordance between the angiographic severity of stenosis and physiological impairment assessed by fractional flow reserve. Reproduced from [28].
FFR
In the non-randomised PLATFORM study, 584 patients with new onset chest pain
were enrolled into two consecutive cohorts [31]. Patients in the first cohort
were assigned to receive usual testing. Those in the second cohort underwent CTCA
instead of planned non-invasive or invasive testing, followed by FFR
The power of FFR
Based upon the positive observational data accrued about the value of FFR
The main advantage that FFR
Given: (a) the association between overall ischaemic burden and outcome; (b)
substantially improved outcomes for PCI directed by pressure wire with
angiography when compared to angiographic assessment alone; (c) the ability of
FFR
The RIPCORD2 trial (Routine Pressure Wire Assessment Versus Conventional
Angiography in the Management of Patients with Coronary Artery Disease) recruited
1100 patients undergoing ICA for the investigation of stable angina or non-ST
elevation MI [37]. The key angiographic inclusion criterion was that participants
were required to have at least one stenosis of 30% or greater in a coronary
vessel of a calibre suitable for revascularisation. Patients were randomised to
assessment and management based upon (a) angiographic appearances alone (ANGIO
alone) or (b) angiographic appearance plus systematic FFR measurement in all
epicardial vessels of sufficient size to be amenable to revascularization (ANGIO
+ FFR). Patients randomised to ANGIO + FFR had a median of 4 vessels investigated
with FFR (interquartile range 3–5). As in the original study, this approach led
to longer cases with greater contrast use, and a pressure-wire related
complication rate of 1.8%. The routine use of FFR did not result in a
significant difference in the co-primary endpoints of (i) total hospital costs
and (ii) quality of life and angina status at 1 year. The rates of all-cause
mortality, non-fatal stroke, non-fatal MI and unplanned revascularisation, the
principal prespecified secondary endpoint, were also similar in both groups. The
experimental strategy resulted in fewer patients requiring additional tests
(1.8% vs. 14.7%, p
The FORECAST trial (Fractional Flow Reserve Derived from Computed Tomography
Coronary Angiography in the Assessment and Management of Stable Chest Pain)
randomised 1400 patients with stable chest pain to either (a) initial testing
with CTCA and selective FFR
Clearly, this question is flawed, because assessment of anatomy and physiology are not mutually exclusive, and, in fact, in many cases can be considered complementary. However, recent data yields a picture that suggests that assessment of atheroma burden is dominant for the diagnostic assessment of patients with suspected CCS. The data presented above are consistent with this notion. SCOT HEART speaks of the power of OMT, without specific requirement for ischaemia testing. ISCHEMIA demonstrates that the optimal treatment for CCS patients is OMT unless they have breakthrough angina (and assuming that left main coronary stenosis has been excluded), and this obviously raises the logical question: why bother with the ischaemia testing in the first place for such patients? Entirely consistent with this, both RIPCORD2 and FORECAST demonstrate no advantage to routine assessment of ischaemia in patients requiring a diagnostic test for suspected CCS.
In addition to this convincing body of evidence, post hoc analyses of
both PROMISE and ISCHEMIA provide some insight into why atheroma burden seems
more important. The PROMISE trial randomised over 9000 patients with stable chest
pain to CTCA or routine clinical assessment. In a follow up paper, the authors
looked at the association between incremental burden of ischaemia and atheroma
and the composite primary endpoint (death, MI or hospitalisation for unstable
angina) [42]. Ischaemia was assessed using exercise electrocardiography, nuclear
stress or stress echocardiography. When the test findings were stratified as
mildly, moderately, or severely abnormal, hazard ratios (compared to a normal
test result) increased proportionally for CTCA (2.94, 7.67, 10.13; all p
The results of both RIPCORD2 and FORECAST do not support a routine assessment of ischaemia at the stage of the diagnostic angiogram. Further, whilst FORECAST yielded a significant reduction in the need for invasive coronary angiography, which is a valuable result both for patients and for hospital efficiency, neither trial demonstrated significant cost savings. The results are consistent with the notion that the initial assessment of patients with stable chest pain can be based around atheroma burden by CTCA, and that the initial management of patients found to have atheroma should then be OMT. This algorithm is consistent with the findings of ISCHEMIA, and has the consequence that only those patients with ongoing angina after full OMT is deployed need to be considered for revascularisation (Fig. 2, Ref. [44]). It is important to note, however, that if the chosen mode of revascularisation is PCI, then FFR or iFR guidance of this procedure would, indeed, be associated with a better, and cheaper, outcome.
Proposed pathway for the investigation and management of patients with stable chest pain. Reproduced from [44].
In the future, tests of coronary physiology will become simpler and quicker to
obtain. For non-invasive assessment, the computation of FFR
AS and NC made substantial contributions to the conceptualization and writing of the manuscript. AS prepared the original draft. NC reviewed the draft and supervised. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
This research received no external funding.
Nick Curzen—unrestricted grants from HeartFlow, Boston Scientific, Beckmann Coulter; speaker fees/consultancy from HeartFlow, Boston Scientific, Abbott, Edwards and travel sponsorship from HeartFlow, Biosensors, Edwards, Medtronic. Nick Curzen is serving as one of the Editorial Board members of this journal. We declare that Nick Curzen had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Peter Kokkinos. The other author declares no conflicts of interest.